Back to Search
MARA RUBENSTEIN, MD
MD
Pediatrics Physician
NPI: 1962412874Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
4301081875(MI)
Research & Publications (20)
Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
PMID 12616956·Methods Find Exp Clin Pharmacol·2002
8-other
Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines.
PMID 11876021·Methods Find Exp Clin Pharmacol·2001
8-other
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
PMID 19533419·Med Oncol·2010
8-other
Regenerative patterning in Swarm Robots: mutual benefits of research in robotics and stem cell biology.
PMID 19557691·Int J Dev Biol·2009
7-preclinical
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
PMID 18686047·Med Oncol·2009
4-observational
Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease.
PMID 17879274·Inflamm Bowel Dis·2008
8-other
Do intra-tumor alkaline micro-regions represent additional therapeutically privileged sites?
PMID 18364249·Med Hypotheses·2008
7-preclinical
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
PMID 17972023·Med Oncol·2008
8-other
To what extent are the "sets" of biologic properties expressed by hypoxic cancer cells and by cancer "stem" cells equivalent, intersecting, disjoint or complementary? Some implications for the design of cancer therapies.
PMID 16934948·Med Hypotheses·2007
7-preclinical
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
PMID 17541843·J Drug Target·2007
7-preclinical
Outcome of a national Israeli cohort of pediatric systemic lupus erythematosus.
PMID 17402372·Lupus·2007
8-other
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
PMID 17917084·Med Oncol·2007
8-other
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
PMID 17848743·Med Oncol·2007
4-observational
Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
PMID 17136230·Methods Find Exp Clin Pharmacol·2006
8-other
Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
PMID 16870352·Med Hypotheses·2006
8-other
Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
PMID 16023790·Med Hypotheses·2005
8-other
Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis.
PMID 16192687·J Biomed Biotechnol·2005
8-other
Potassium-titanyl-phosphate laser laparoscopic partial nephrectomy without hilar clamping in the survival calf model.
PMID 16094075·J Urol·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 31500 TELEGRAPH RD, 105
BINGHAM FARMS, MI 48025 - Phone
- (248) 540-8700
Quick Facts
- NPI
- 1962412874
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile